Insulin-like growth factor system in cancer: Novel targeted therapies

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Brahmkhatri, Varsha P ^a   Prasanna, Chinmayi ^a   Atreya, Hanudatta S ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NANOTUBE; NATURAL PRODUCT; PROTEINASE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; IGF1R PROTEIN, HUMAN; SOMATOMEDIN BINDING PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTISENSE THERAPY; AUTOCRINE EFFECT; BREAST CANCER; BREAST TUMOR; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER THERAPY; CARCINOGENICITY; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; EARLY CANCER; GENE THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; METASTASIS; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARACRINE SIGNALING; PHYTOCHEMISTRY; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SIRNA THERAPY; TRANSGENIC MOUSE; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; NEOPLASMS; RECEPTORS, SOMATOMEDIN; SOMATOMEDINS;

EID: 84926442274     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/538019     Document Type: Review

References (239)

1. D. R. Clemmons, "Value of insulin-like growth factor system markers in the assessment of growth hormone status," Endocrinology and Metabolism Clinics of North America, Vol. 36, no. 1, pp. 109-129, 2007.
2. S. M. Firth and R. C. Baxter, "Cellular actions of the insulin-like growth factor binding proteins," Endocrine Reviews, Vol. 23, no. 6, pp. 824-854, 2002.
3. L. E. H. Smith, W. Shen, C. Perruzzi et al., "Regulation of vascular endothelial growth factor-dependent retinal neovas-cularization by insulin-like growth factor-1 receptor," Nature Medicine, Vol. 5, no. 12, pp. 1390-1395, 1999.
4. M. J. Horney, D. W. Shirley, D. T. Kurtz, and S. A. Rosenzweig, "Elevated glucose increases mesangial cell sensitivity to insulinlike growth factor I," American Journal of Physiology: Renal Physiology, Vol. 274, no. 6, part 2, pp. F1045-F1053, 1998.
5. M. G. Slomiany and S. A. Rosenzweig, "IGF-1-induced VEGF and IGFBP-3 secretion correlates with increased HIF-1α expression and activity in retinal pigment epithelial cell line D407," Investigative Ophthalmology & Visual Science, Vol. 45, no. 8, pp. 2838-2847, 2004.
6. K. T. Flaherty, F. S. Hodi, and D. E. Fisher, "From genes to drugs: targeted strategies for melanoma," Nature Reviews Cancer, Vol. 12, no. 5, pp. 349-361, 2012.
7. M. J. Higgins and J. Baselga, "Targeted therapies for breast cancer," Journal of Clinical Investigation, Vol. 121, no. 10, pp. 3797-3803, 2011.
8. A. M. Scott, J. D. Wolchok, and L. J. Old, "Antibody therapy of cancer," Nature Reviews Cancer, Vol. 12, no. 4, pp. 278-287, 2012.
9. P. Chames, M. van Regenmortel, E. Weiss, and D. Baty, "Therapeutic antibodies: successes, limitations and hopes for the future," British Journal of Pharmacology, Vol. 157, no. 2, pp. 220-233, 2009.
10. S. A. Rosenzweig and H. S. Atreya, "Defining the pathway to insulin-like growth factor system targeting in cancer," Biochemical Pharmacology, Vol. 80, no. 8, pp. 1115-1124, 2010.
11. H. Werner, G. G. Re, I. A. Drummond et al., "Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product," Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, no. 12, pp. 5828-5832, 1993.
12. A. O. W. Stretton, "The first sequence: fred Sanger and insulin," Genetics, Vol. 162, no. 2, pp. 527-532, 2002.
13. Z. Qu, J. C. Chow, P.-R. Ling, T. R. Ziegler, B. R. Bistrian, and R. J. Smith, "Tissue-specific effects of chronic dietary protein restriction and gastrostomy on the insulin-like growth factor-I pathway in the liver and colon of adult rats," Metabolism: Clinical and Experimental, Vol. 46, no. 6, pp. 691-697, 1997.
14. W. D. Salmon Jr. and W. H. Daughaday, "A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro," The Journal of Laboratory and Clinical Medicine, Vol. 49, no. 6, pp. 825-836, 1957.
15. E. Rinderknecht and R. E. Humbel, "The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin," The Journal of Biological Chemistry, Vol. 253, no. 8, pp. 2769-2776, 1978.
16. T. L. Blundell, S. Bedarkar, and R. E. Humbel, "Tertiary structures, receptor binding, and antigenicity of insulinlike growth factors," Federation Proceedings, Vol. 42, no. 9, pp. 2592-2597, 1983.
17. J. Wang, J. Zhou, and C. A. Bondy, "Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy," The FASEB Journal, Vol. 13, no. 14, pp. 1985-1990, 1999.
18. A. J. D'Ercole, G. T. Applewhite, and L. E. Underwood, "Evidence that somatomedin is synthesized by multiple tissues in the fetus," Developmental Biology, Vol. 75, no. 2, pp. 315-328, 1980.
19. C. T. Roberts Jr., S. R. Lasky, W. L. Lowe Jr., W. T. Seaman, and D. LeRoith, "Molecular cloning of rat insulin-like growth factor I complementary deoxyribonucleic acids: differential messenger ribonucleic acid processing and regulation by growth hormone in extrahepatic tissues," Molecular Endocrinology, Vol. 1, no. 3, pp. 243-248, 1987.
20. V. K. M. Han, P. K. Lund, D. C. Lee, and A. J. D'Ercole, "Expression of somatomedin/insulin-like growth factor messenger ribonucleic acids in the human fetus: identification, characterization, and tissue distribution," The Journal of Clinical Endocrinology & Metabolism, Vol. 66, no. 2, pp. 422-429, 1988.
21. W. L. Lowe Jr., S. R. Lasky, D. LeRoith, and C. T. Roberts Jr., "Distribution and regulation of rat insulin-like growth factor I messenger ribonucleic acids encoding alternative carboxyterminal E-peptides: evidence for differential processing and regulation in liver," Molecular Endocrinology, Vol. 2, no. 6, pp. 528-535, 1988.
22. O. G. P. Isaksson, J. O. Jansson, and I. A. M. Gause, "Growth hormone stimulates longitudinal bone growth directly," Science, Vol. 216, no. 4551, pp. 1237-1239, 1982.
23. M. N. Pollak, E. S. Schernhammer, and S. E. Hankinson, "Insulin-like growth factors and neoplasia," Nature Reviews Cancer, Vol. 4, no. 7, pp. 505-518, 2004.
24. J. Wang, W. Niu, D. P. Witte et al., "Overexpression of insulinlike growth factor-binding protein-4 (IGFBP-4) in smooth muscle cells of transgenic mice through a smooth muscle α-actin-IGFBP-4 fusion gene induces smooth muscle hypoplasia," Endocrinology, Vol. 139, no. 5, pp. 2605-2614, 1998.
25. P. Ye, J. Carson, and A. J. D'Ercole, "In vivo actions of insulinlike growth factor-I (IGF-I) on brain myelination: studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic mice," The Journal of Neuroscience, Vol. 15, no. 11, pp. 7344-7356, 1995.
26. A. J. D'Ercole, Z. Dai, Y. Xing et al., "Brain growth retardation due to the expression of human insulin like growth factor binding protein-1 in transgenic mice: an in vivo model for the analysis of igf function in the brain," Developmental Brain Research, Vol. 82, no. 1-2, pp. 213-222, 1994.
27. W. Ni, K. Rajkumar, J. I. Nagy, and L. J. Murphy, "Impaired brain development and reduced astrocyte response to injury in transgenic mice expressing IGF binding protein-1," Brain Research, Vol. 769, no. 1, pp. 97-107, 1997.
28. D. LeRoith, H. Werner, D. Beitner-Johnson, and C. T. Roberts Jr., "Molecular and cellular aspects of the insulin-like growth factor I receptor," Endocrine Reviews, Vol. 16, no. 2, pp. 143-163, 1995.
29. C. E. H. Stewart and P. Rotwein, "Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors," Physiological Reviews, Vol. 76, no. 4, pp. 1005-1026, 1996.
30. J. I. Jones and D. R. Clemmons, "Insulin-like growth factors and their binding proteins: biological actions," Endocrine Reviews, Vol. 16, no. 1, pp. 3-34, 1995.
31. H. Yu and T. Rohan, "Role of the insulin-like growth factor family in cancer development and progression," Journal of the National Cancer Institute, Vol. 92, no. 18, pp. 1472-1489, 2000.
32. L. Sepp-Lorenzino, "Structure and function of the insulin-like growth factor I receptor," Breast Cancer Research and Treatment, Vol. 47, no. 3, pp. 235-253, 1998.
33. G. Steele-Perkins, J. Turner, J. C. Edman et al., "Expression and characterization of a functional human insulin-like growth factor I receptor," The Journal of Biological Chemistry, Vol. 263, no. 23, pp. 11486-11492, 1988.
34. A. L. Frattali and J. E. Pessin, "Relationship between α subunit ligand occupancy and β subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors," The Journal of Biological Chemistry, Vol. 268, no. 10, pp. 7393-7400, 1993.
35. D. Chrysis, A. S. Calikoglu, P. Ye, and A. J. D'Ercole, "Insulinlike growth factor-I overexpression attenuates cerebellar apoptosis by altering the expression of Bcl family proteins in a developmentally specific manner," The Journal of Neuroscience, Vol. 21, no. 5, pp. 1481-1489, 2001.
36. K. D. Dentremont, P. Ye, A. J. D'Ercole, and J. R. O'Kusky, "Increased insulin-like growth factor-I (IGF-I)expression during early postnatal development differentially increases neuron number and growth in medullary nuclei of the mouse," Developmental Brain Research, Vol. 114, no. 1, pp. 135-141, 1999.
37. G. Zhao, M.-C. Monier-Faugere, M. C. Langub et al., "Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation," Endocrinology, Vol. 141, no. 7, pp. 2674-2682, 2000.
38. K. Reiss, W. Cheng, A. Ferber et al., "Overexpression of insulinlike growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice," Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, no. 16, pp. 8630-8635, 1996.
39. M. E. Coleman, F. Demayo, R. Geske, C. Montgomery, and R. J. Schwartz, "Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice," The Journal of Biological Chemistry, Vol. 270, no. 20, pp. 12109-12116, 1995.
40. A. J. Oates, L. M. Schumaker, S. B. Jenkins et al., "The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene," Breast Cancer Research and Treatment, Vol. 47, no. 3, pp. 269-281, 1998.
41. D. O. Morgan, J. C. Edman, D. N. Standring et al., "Insulin-like growth factor II receptor as a multifunctional binding protein," Nature, Vol. 329, no. 6137, pp. 301-307, 1987.
42. A. Oshima, C. M. Nolan, J. W. Kyle, J. H. Grubb, and W. S. Sly, "The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in cos cells," The Journal of Biological Chemistry, Vol. 263, no. 5, pp. 2553-2562, 1988.
43. T. Braulke, "Type-2 IGF receptor: a multi-ligand binding protein," Hormone and Metabolic Research, Vol. 31, no. 2-3, pp. 242-246, 1999.
44. Y. Yang, A. Hoeflich, O. Butenandt, and W. Kiess, "Opposite regulation of IGF-I and IGF-I receptor mRNA and concomitant changes of GH receptor and IGF-II/M6P receptor mRNA in human IM-9 lymphoblasts," Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Vol. 1310, no. 3, pp. 317-324, 1996.
45. C. Hernández-Sánchez, H. Werner, C. T. Roberts Jr. et al., "Differential regulation of insulin-like growth factor-I (IGF-I) receptor gene expression by IGF-I and basic fibroblastic growth factor," The Journal of Biological Chemistry, Vol. 272, no. 8, pp. 4663-4670, 1997.
46. S. M. Rosenthal, E. J. Brown, A. Brunetti, and I. D. Goldfine, "Fibroblast growth factor inhibits insulin-like growth factor-II (IGF-II) gene expression and increases IGF-I receptor abundance in BC3H-1 muscle cells," Molecular Endocrinology, Vol. 5, no. 5, pp. 678-684, 1991.
47. M. Rubini, H. Werner, E. Gandini, C. T. Roberts Jr., D. Leroith, and R. Baserga, "Platelet-derived growth factor increases the activity of the promoter of the insulin-like growth factor-1 (IGF-1) receptor gene," Experimental Cell Research, Vol. 211, no. 2, pp. 374-379, 1994.
48. H. Werner, "Dysregulation of the Type 1 IGF receptor as a paradigm in tumor progression," Molecular and Cellular Endocrinology, Vol. 141, no. 1-2, pp. 1-5, 1998.
49. H. Werner, E. Karnieli, F. J. Rauscher III, and D. LeRoith, "Wildtype and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene," Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, no. 16, pp. 8318-8323, 1996.
50. M. Prisco, A. Hongo, M. G. Rizzo, A. Sacchi, and R. Baserga, "The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal," Molecular and Cellular Biology, Vol. 17, no. 3, pp. 1084-1092, 1997.
51. J. P. Thissen, J. M. Ketelslegers, and L. E. Underwood, "Nutritional regulation of the insulin-like growth factors," Endocrine Reviews, Vol. 15, no. 1, pp. 80-101, 1994.
52. W. Zhang, W. H. Thornton Jr., and R. S. MacDonald, "Insulin - like growth factor-I and II receptor expression in rat colon mucosa are affected by dietary lipid intake," Journal of Nutrition, Vol. 128, no. 2, pp. 158-165, 1998.
53. A. Hoeflich, Y. Yang, W. Rascher et al., "Coordinate expression of insulin-like growth factor II (IGF-II) and IGP-II/mannose-6-phosphate receptor mRNA and stable expression of IGF-I receptor mRNA during differentiation of human colon carcinoma cells (Caco-2)," European Journal of Endocrinology, Vol. 135, no. 1, pp. 49-59, 1996.
54. M. Takigawa, T. Okawa, H.-O. Pan et al., "Insulin-like growth factors I and II are autocrine factors in stimulating proteoglycan synthesis, a marker of differentiated chondrocytes, acting through their respective receptors on a clonal human chondrosarcoma-derived chondrocyte cell line, HCS-2/8," Endocrinology, Vol. 138, no. 10, pp. 4390-4400, 1997.
55. W. Kiess, L. A. Greenstein, R. M. White, L. Lee, M. M. Rechler, and S. P. Nissley, "Type II insulin-like growth factor receptor is present in rat serum," Proceedings of the National Academy of Sciences of the United States of America, Vol. 84, no. 21, pp. 7720-7724, 1987.
56. R. G. MacDonald, M. A. Tepper, K. B. Clairmont, S. B. Perregaux, and M. P. Czech, "Serum form of the rat insulin-like growth factor II/mannose 6-phosphate receptor is truncated in the carboxyl-terminal domain," The Journal of Biological Chemistry, Vol. 264, no. 6, pp. 3256-3261, 1989.
57. K. J. Valenzano, J. Remmler, and P. Lobel, "Soluble insulinlike growth factor II/mannose 6-phosphate receptor carries multiple high molecular weight forms of insulin-like growth factor II in fetal bovine serum," The Journal of Biological Chemistry, Vol. 270, no. 27, pp. 16441-16448, 1995.
58. S. Zaina and S. Squire, "The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms," The Journal of Biological Chemistry, Vol. 273, no. 44, pp. 28610-28616, 1998.
59. Y. Xu, A. Papageorgiou, and C. Polychronakos, "Developmental regulation of the soluble form of insulin-like growth factor-II/mannose 6-phosphate receptor in human serum and amniotic fluid," Journal of Clinical Endocrinology and Metabolism, Vol. 83, no. 2, pp. 437-442, 1998.
60. M. Costello, R. C. Baxter, and C. D. Scott, "Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum: measurement by enzyme-linked immunosorbent assay," The Journal of Clinical Endocrinology & Metabolism, Vol. 84, no. 2, pp. 611-617, 1999.
61. J. Zapf, M. Waldvogel, and E. R. Froesch, "Binding of nonsup-pressible insulinlike activity to human serum: evidence for a carrier protein," Archives of Biochemistry and Biophysics, Vol. 168, no. 2, pp. 638-645, 1975.
62. R. L. Hintz and F. Liu, "Demonstration of specific plasma protein binding sites for somatomedin," The Journal of Clinical Endocrinology and Metabolism, Vol. 45, no. 5, pp. 988-995, 1977.
63. M. M. Rechler and A. L. Brown, "Insulin-like growth factor binding proteins: gene structure and expression," Growth Regulation, Vol. 2, no. 2, pp. 55-68, 1992.
64. L. A. Bach and M. M. Rechler, "Insulin-like growth factor binding proteins," Diabetes Reviews, Vol. 3, no. 1, pp. 38-61, 1995.
65. G. M. Neumann and L. A. Bach, "The N-terminal disulfide linkages of human insulin-like growth factor-binding protein-6 (hIGFBP-6) and hIGFBP-1 are different as determined by mass spectrometry," The Journal of Biological Chemistry, Vol. 274, no. 21, pp. 14587-14594, 1999.
66. R. Durai, M. Davies, W. Yang et al., "Biology of insulin-like growth factor binding protein-4 and its role in cancer (review)," International Journal of Oncology, Vol. 28, no. 6, pp. 1317-1325, 2006.
67. B. Kübler, S. Cowell, J. Zapf, and T. Braulke, "Proteolysis of insulin-like growth factor binding proteins by a novel 50-kilodalton metalloproteinase in human pregnancy serum," Endocrinology, Vol. 139, no. 4, pp. 1556-1563, 1998.
68. J. C. Chen, Z. M. Shao, M. S. Sheikh et al., "Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line," Journal of Cellular Physiology, Vol. 158, no. 1, pp. 69-78, 1994.
69. P. M. Yamada and K.-W. Lee, "Perspectives in mammalian IGFBP-3 biology: local vs. systemic action," American Journal of Physiology - Cell Physiology, Vol. 296, no. 5, pp. C954-C976, 2009.
70. D. Romero, C. O'Neill, A. Terzic et al., "Endoglin regulates cancer-stromal cell interactions in prostate tumors," Cancer Research, Vol. 71, no. 10, pp. 3482-3493, 2011.
71. R. Rajah, L. Katz, S. Nunn, P. Solberg, T. Beers, and P. Cohen, "Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth," Cytokine and Growth Factor Reviews, Vol. 6, no. 2-4, pp. 273-284, 1995.
72. M. Takaoka, H. Harada, C. D. Andl et al., "Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3," Cancer Research, Vol. 64, no. 21, pp. 7711-7723, 2004.
73. J. L. Fowlkes, "Insulinlike growth factor-binding protein proteolysis: an emerging paradigm in insulinlike growth factor physiology," Trends in Endocrinology and Metabolism, Vol. 8, no. 8, pp. 299-306, 1997.
74. J. L. Fowlkes, J. J. Enghild, K. Suzuki, and H. Nagase, "Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures," Journal of Biological Chemistry, Vol. 269, no. 41, pp. 25742-25746, 1994.
75. R. P. Verma and C. Hansch, "Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs," Bioorganic & Medicinal Chemistry, Vol. 15, no. 6, pp. 2223-2268, 2007.
76. J. L. Fowlkes, K. M. Thrailkill, D. M. Serra, K. Suzuki, and H. Nagase, "Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases," Cytokine and Growth Factor Reviews, Vol. 6, no. 2-4, pp. 255-263, 1995.
77. H. A. Coppock, A. White, J. D. Aplin, and M. Westwood, "Matrix metalloprotease-3 and -9 proteolyze insulin-like growth factor-binding protein-1," Biology of Reproduction, Vol. 71, no. 2, pp. 438-443, 2004.
78. R. Rajah, R. V. Nachajon, M. H. Collins, H. Hakonarson, M. M. Grunstein, and P. Cohen, "Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle," The American Journal of Respiratory Cell and Molecular Biology, Vol. 20, no. 2, pp. 199-208, 1999.
79. C. A. Conover, G. F. Faessen, K. E. Ilg et al., "Pregnancy-associated plasma protein-A is the insulin-like growth factor binding protein-4 protease secreted by human ovarian granulosa cells and is a marker of dominant follicle selection and the corpus luteum," Endocrinology, Vol. 142, no. 5, pp. 2155-2158, 2001.
80. S. Mark, B. Kübler, S. Höning et al., "Diversity of human insulin-like growth factor (IGF) binding protein-2 fragments in plasma: primary structure, IGF-binding properties, and disulfide bonding pattern," Biochemistry, Vol. 44, no. 9, pp. 3644-3652, 2005.
81. M. Zhang, E. P. Smith, H. Kuroda, W. Banach, S. D. Chernausek, and J. A. Fagin, "Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice results in IGFBP-4 stabilization and smooth muscle hypotrophy," The Journal of Biological Chemistry, Vol. 277, no. 24, pp. 21285-21290, 2002.
82. L. A. Bach, P. Fu, and Z. Yang, "Insulin-like growth factorbinding protein-6 and cancer," Clinical Science, Vol. 124, no. 4, pp. 215-229, 2013.
83. A. J. Ryan, S. Napoletano, P. A. Fitzpatrick, C. A. Currid, N. C. O'Sullivan, and J. H. Harmey, "Expression of a proteaseresistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer," British Journal of Cancer, Vol. 101, no. 2, pp. 278-286, 2009.
84. C.-L. Soh, K. McNeil, C.M. Owczarek et al., "Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer," British Journal of Cancer, Vol. 110, no. 12, pp. 2855-2864, 2014.
85. Y. Oh, S. R. Nagalla, Y. Yamanaka, H.-S. Kim, E. Wilson, and R. G. Rosenfeld, "Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7: recombinant human mac25 protein specifically binds IGF-I and -II," The Journal of Biological Chemistry, Vol. 271, no. 48, pp. 30322-30325, 1996.
86. M. R. Corkins, J. A. Vanderhoof, D. H. Slentz, R. G. MacDonald, and J. H. Y. Park, "Growth stimulation by transfection of intestinal epithelial cells with an antisense insulin-like growth factor binding protein-2 construct," Biochemical and Biophysical Research Communications, Vol. 211, no. 3, pp. 707-713, 1995.
87. O. M. Casey, R. Fitzpatrick, J. O. McInerney, D. G. Morris, R. Powell, and J. M. Sreenan, "Analysis of gene expression in the bovine corpus luteum through generation and characterisation of 960 ESTs," Biochimica et Biophysica Acta: Gene Structure and Expression, Vol. 1679, no. 1, pp. 10-17, 2004.
88. F. Domínguez, S. Avila, A. Cervero et al., "A combined approach for gene discovery identifies insulin-like growth factor-binding protein-related protein I as a new gene implicated in human endometrial receptivity," The Journal of Clinical Endocrinology and Metabolism, Vol. 88, no. 4, pp. 1849-1857, 2003.
89. S.-A. Wandji, J. E. Gadsby, J. A. Barber, and J. M. Hammond, "Messenger ribonucleic acids for mac25 and connective tissue growth factor (CTGF) are inversely regulated during folliculo-genesis and early luteogenesis," Endocrinology, Vol. 141, no. 7, pp. 2648-2657, 2000.
90. C. C. Sprenger, M. E. Vail, K. Evans, J. Simurdak, and S. R. Plymate, "Over-expression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis," Oncogene, Vol. 21, no. 1, pp. 140-147, 2002.
91. C. Rupp, M. Scherzer, A. Rudisch et al., "IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction," Oncogene, 2014.
92. S. Zhu, F. Xu, J. Zhang, W. Ruan, and M. Lai, "Insulin-like growth factor binding protein-related protein 1 and cancer," Clinica Chimica Acta, Vol. 431, pp. 23-32, 2014.
93. W. Jiang, C. Xiang, S. Cazacu, C. Brodie, and T. Mikkelsen, "Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration," Neoplasia, Vol. 10, no. 12, pp. 1335-1342, 2008.
94. V. Evdokimova, C. E. Tognon, T. Benatar et al., "IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors," Science Signaling, Vol. 5, no. 255, article ra92, 2012.
95. T. Fukushima and H. Kataoka, "Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma," Anticancer Research, Vol. 27, no. 6, pp. 3685-3692, 2007.
96. F. E. Carrick, B. E. Forbes, and J. C. Wallace, "BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains," The Journal of Biological Chemistry, Vol. 276, no. 29, pp. 27120-27128, 2001.
97. G. D. Hobba, A. Löthgren, E. Holmberg, B. E. Forbes, G. L. Francis, and J. C. Wallace, "Alanine screening mutagenesis establishes tyrosine 60 of bovine insulin-like growth factor binding protein-2 as a determinant of insulin-like growth factor binding," The Journal of Biological Chemistry, Vol. 273, no. 31, pp. 19691-19698, 1998.
98. G. D. Hobba, B. E. Forbes, E. J. Parkinson, G. L. Francis, and J. C. Wallace, "The insulin-like growth factor (IGF) binding site of bovine insulin-like growth factor binding protein-2 (biGFBP-2) probed by iodination," The Journal of Biological Chemistry, Vol. 271, no. 48, pp. 30529-30536, 1996.
99. B. E. Forbes, D. Turner, S. J. Hodge, K. A. McNeil, G. Forsberg, and J. C. Wallace, "Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain," The Journal of Biological Chemistry, Vol. 273, no. 8, pp. 4647-4652, 1998.
100. M.M. Kibbey, M.J. Jameson, E.M. Eaton, and S.A. Rosenzweig, "Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to insulin-like growth factor-1 binding," Molecular Pharmacology, Vol. 69, no. 3, pp. 833-845, 2006.
101. F. E. Carrick, M. G. Hinds, K. A. McNeil, J. C. Wallace, B. E. Forbes, and R. S. Norton, "Interaction of insulin-like growth factor (IGF)-I and -II with IGF binding protein-2: mapping the binding surfaces by nuclear magnetic resonance," Journal of Molecular Endocrinology, Vol. 34, no. 3, pp. 685-698, 2005.
102. Z. Kuang, S. Yao, K. A. McNeil et al., "Cooperativity of the N- and C-terminal domains of insulin-like growth factor (IGF) binding protein 2 in IGF binding," Biochemistry, Vol. 46, no. 48, pp. 13720-13732, 2007.
103. B. E. Forbes, P. McCarthy, and R. S. Norton, "Insulin-like growth factor binding proteins: a structural perspective," Frontiers in Endocrinology, Vol. 3, article 38, 2012.
104. M. Swain, M. G. Slomiany, S. A. Rosenzweig, and H. S. Atreya, "High-yieldbacterial expression and structural characterization of recombinant human insulin-like growth factor binding protein-2," Archives of Biochemistry and Biophysics, Vol. 501, no. 2, pp. 195-200, 2010.
105. M. Swain, R. Thirupathi, B. Krishnarjuna et al., "Spontaneous and reversible self-assembly of a polypeptide fragment of insulin-like growth factor binding protein-2 into fluorescent nanotubular structures," Chemical Communications, Vol. 46, no. 2, pp. 216-218, 2010.
106. S. Y. Kim, J. A. Toretsky, D. Scher, and L. J. Helman, "The role of IGF-1R in pediatric malignancies," The Oncologist, Vol. 14, no. 1, pp. 83-91, 2009.
107. M. M. Chitnis, J. S. P. Yuen, A. S. Protheroe, M. Pollak, and V. M. Macaulay, "The type 1 insulin-like growth factor receptor pathway," Clinical Cancer Research, Vol. 14, no. 20, pp. 6364-6370, 2008.
108. K. Takeuchi and F. Ito, "Receptor tyrosine kinases and targeted cancer therapeutics," Biological and Pharmaceutical Bulletin, Vol. 34, no. 12, pp. 1774-1780, 2011.
109. R. Baserga, F. Peruzzi, and K. Reiss, "The IGF-1 receptor in cancer biology," International Journal of Cancer, Vol. 107, no. 6, pp. 873-877, 2003.
110. A. G. Renehan, M. Zwahlen, C. Minder, S. T. O'Dwyer, S. M. Shalet, and M. Egger, "Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and metaregression analysis," The Lancet, Vol. 363, no. 9418, pp. 1346-1353, 2004.
111. H. Cui, M. Cruz-Correa, F. M. Giardiello et al., "Loss of IGF2 imprinting: a potential marker of colorectal cancer risk," Science, Vol. 299, no. 5613, pp. 1753-1755, 2003.
112. G. E. Krassas, N. Pontikides, T. Kaltsas et al., "Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease," The Journal of Clinical Endocrinology and Metabolism, Vol. 88, no. 1, pp. 132-135, 2003.
113. P. Vorwerk, H. Wex, C. Bessert, B. Hohmann, U. Schmidt, and U. Mittler, "Loss of imprinting of IGF-II gene in children with acute lymphoblastic leukemia," Leukemia Research, Vol. 27, no. 9, pp. 807-812, 2003.
114. C. M. Coutinho-Camillo, M. M. Brentani, O. Butugan, H. Torloni, and M. A. Nagai, "Relaxation of imprinting of IGFII gene in juvenile nasopharyngeal angiofibromas," Diagnostic Molecular Pathology, Vol. 12, no. 1, pp. 57-62, 2003.
115. O. Ogawa, D. M. Becroft, I. M. Morison et al., "Constitutional relaxation of insulin-like growth factor II gene imprinting associated with Wilms' tumour and gigantism," Nature Genetics, Vol. 5, no. 4, pp. 408-412, 1993.
116. J. Zhang, J. M. Trent, and P. S. Meltzer, "Rapid isolation and characterization of amplified DNA by chromosome microdissection: Identification of IGF1R amplification in malignant melanoma," Oncogene, Vol. 8, no. 10, pp. 2827-2831, 1993.
117. G. Armengol, S. Knuutila, F. Lluís, G. Capellà, R. Miró, and M. R. Caballín, "DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma," Cancer Genetics and Cytogenetics, Vol. 116, no. 2, pp. 133-141, 2000.
118. A. Almeida, M. Muleris, B. Dutrillaux, and B. Malfoy, "The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer," Genes Chromosomes and Cancer, Vol. 11, no. 1, pp. 63-65, 1994.
119. A. Belfiore, "The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer," Current Pharmaceutical Design, Vol. 13, no. 7, pp. 671-686, 2007.
120. E. A. Bohula, M. P. Playford, and V. M. Macaulay, "Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment," Anti-Cancer Drugs, Vol. 14, no. 9, pp. 669-682, 2003.
121. J. S. P. Yuen and V. M. Macaulay, "Targeting the type 1 insulinlike growth factor receptor as a treatment for cancer," Expert Opinion on Therapeutic Targets, Vol. 12, no. 5, pp. 589-603, 2008.
122. E. Surmacz, "Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor," Oncogene, Vol. 22, no. 42, pp. 6589-6597, 2003.
123. I. Singh, H. Amin, B. Rah, and A. Goswami, "Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer," Frontiers in Bioscience - Scholar, Vol. 5, no. 1, pp. 231-246, 2013.
124. L. Mohanraj and Y. Oh, "Targeting IGF-I, IGFBPs and IGF-I receptor system in cancer: the current and future in breast cancer therapy," Recent Patents on Anti-Cancer Drug Discovery, Vol. 6, no. 2, pp. 166-177, 2011.
125. J. Riedemann and V. M. Macaulay, "IGF1R signalling and its inhibition," Endocrine-Related Cancer, Vol. 13, no. 1, pp. S33-S43, 2006.
126. M. Pollak, "The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology," Clinical Cancer Research, Vol. 18, no. 1, pp. 40-50, 2012.
127. F. I. Arnaldez and L. J. Helman, "Targeting the insulin growth factor receptor 1," Hematology/Oncology Clinics of North America, Vol. 26, no. 3, pp. 527-542, 2012.
128. A. Arcaro, "Targeting the insulin-like growth factor-1 receptor in human cancer," Frontiers in Pharmacology, Vol. 4, article 30, 2013.
129. D. Yee, "Insulin-like growth factor receptor inhibitors: baby or the bathwater?" Journal of the National Cancer Institute, Vol. 104, no. 13, pp. 975-981, 2012.
130. V. M. Macaulay, "The IGF receptor as anticancer treatment target," Novartis Foundation Symposium, Vol. 262, pp. 235-246, 2004.
131. Y. Adachi, C. T. Lee, and D. P. Carbone, "Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy," Novartis Foundation Symposium, Vol. 262, pp. 177-268, 2004.
132. Y. Adachi, C. Lee, K. Coffee et al., "Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines," Gastroenterology, Vol. 123, no. 4, pp. 1191-1204, 2002.
133. C. Liu, Z. Zhang, H. Tang, Z. Jiang, L. You, and Y. Liao, "Crosstalk between IGF-1R and other Tumor Promoting Pathways," Current Pharmaceutical Design, Vol. 20, no. 17, pp. 2912-2921, 2014.
134. M. Xue, X. Cao, Y. Zhong et al., "Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives," Current Pharmaceutical Design, Vol. 18, no. 20, pp. 2901-2913, 2012.
135. J. van der Veeken, S. Oliveira, R. M. Schiffelers, G. Storm, P. M. P. Van Bergen En Henegouwen, and R. C. Roovers, "Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: Implications for cancer therapy," Current Cancer Drug Targets, Vol. 9, no. 6, pp. 748-760, 2009.
136. M. Mancini, M. B. Gariboldi, E. Taiana et al., "Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells," British Journal of Cancer, Vol. 110, no. 12, pp. 2865-2873, 2014.
137. A. T. de Souza, G. R. Hankins, M. K. Washington, T. C. Orton, and R. L. Jirtle, "M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity," Nature Genetics, Vol. 11, no. 4, pp. 447-449, 1995.
138. Y. Myal, R. P. C. Shiu, B. Bhaumick, and M. Bala, "Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture," Cancer Research, Vol. 44, no. 12, part 1, pp. 5486-5490, 1984.
139. S. E. Hankinson, W. C. Willett, G. A. Colditz et al., "Circulating concentrations of insulin-like growth factor-I and risk of breast cancer," The Lancet, Vol. 351, no. 9113, pp. 1393-1396, 1998.
140. H. Yu, M. R. Spitz, J. Mistry, J. Gu, W. K. Hong, and X. Wu, "Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis," Journal of the National Cancer Institute, Vol. 91, no. 2, pp. 151-156, 1999.
141. J. Ma, M. N. Pollak, E. Giovannucci et al., "Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3," Journal of the National Cancer Institute, Vol. 91, no. 7, pp. 620-625, 1999.
142. R. Shi, H. J. Berkel, and H. Yu, "Insulin-like growth factor-I and prostate cancer: a meta-analysis," British Journal of Cancer, Vol. 85, no. 7, pp. 991-996, 2001.
143. J. M. Chan, M. J. Stampfer, E. Giovannucci et al., "Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study," Science, Vol. 279, no. 5350, pp. 563-566, 1998.
144. Y. Wu, K. Cui, K. Miyoshi et al., "Reduced circulating insulinlike growth factor I levels delay the onset of chemically and genetically induced mammary tumors," Cancer Research, Vol. 63, no. 15, pp. 4384-4388, 2003.
145. N. Majeed, M.-J. Blouin, P. J. Kaplan-Lefko et al., "A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model," Oncogene, Vol. 24, no. 29, pp. 4736-4740, 2005.
146. M. Pollak, "Insulin, insulin-like growth factors and neoplasia," Best Practice and Research: Clinical Endocrinology and Metabolism, Vol. 22, no. 4, pp. 625-638, 2008.
147. J. Gao, J. W. Chesebrough, S. A. Cartlidge et al., "Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth," Cancer Research, Vol. 71, no. 3, pp. 1029-1040, 2011.
148. G. T. Tindall, S. S. Ambrose, J. H. Christy, and J. M. Patton, "Hypophysectomy in the treatment of disseminated carcinoma of the breast and prostate gland," Southern Medical Journal, Vol. 69, no. 5, pp. 579-587, 1976.
149. A. Grimberg, "p53 and IGFBP-3: apoptosis and cancer protection," Molecular Genetics and Metabolism, Vol. 70, no. 2, pp. 85-98, 2000.
150. M. J. Moreno, M. Ball, M. Rukhlova et al., "IGFBP-4 anti-angiogenic and anti-tumorigenic effects are associated with anti-cathepsin B activity," Neoplasia, Vol. 15, no. 5, pp. 554-567, 2013.
151. A. Grimberg and P. Cohen, "Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis," Journal of Cellular Physiology, Vol. 183, no. 1, pp. 1-9, 2000.
152. T. Nickerson, H. Miyake, M. E. Gleave, and M. Pollak, "Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins," Cancer Research, Vol. 59, no. 14, pp. 3392-3395, 1999.
153. T. Nickerson and M. Pollak, "Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins," Urology, Vol. 54, no. 6, pp. 1120-1125, 1999.
154. R. C. Baxter, "IGF binding proteins in cancer: mechanistic and clinical insights," Nature Reviews Cancer, Vol. 14, no. 5, pp. 329-341, 2014.
155. J. I. Jones, A. Joseph D'Ercole, C. Camacho-Hubner, and D. R. Clemmons, "Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects on affinity for IGF-I," Proceedings of the National Academy of Sciences of the United States of America, Vol. 88, no. 17, pp. 7481-7485, 1991.
156. J. I. Leu, M. A. S. Crissey, and R. Taub, "Massive hepatic apoptosis associated with TGF-β1 activation after Fas ligand treatment of IGF binding protein-1-deficient mice," The Journal of Clinical Investigation, Vol. 111, no. 1, pp. 129-139, 2003.
157. D. Yee, J. G. Jackson, T. W. Kozelsky, and J. A. Figueroa, "Insulinlike growth factor binding protein 1 expression inhibits insulinlike growth factor I action in MCF-7 breast cancer cells," Cell Growth & Differentiation, Vol. 5, no. 1, pp. 73-77, 1994.
158. D. Diehl, E. Hessel, D. Oesterle et al., "IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis," International Journal of Cancer, Vol. 124, no. 9, pp. 2220-2225, 2009.
159. A. Hoeflich, R. Reisinger, H. Lahm et al., "Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?" Cancer Research, Vol. 61, no. 24, pp. 8601-8610, 2001.
160. V. C. Russo, B. S. Schütt, E. Andaloro et al., "Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion," Endocrinology, Vol. 146, no. 10, pp. 4445-4455, 2005.
161. S. W. Song, G. N. Fuller, A. Khan et al., "IIp45, an insulinlike growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion," Proceedings of the National Academy of Sciences of the United States of America, Vol. 100, no. 2, pp. 13970-13975, 2003.
162. G. K. Wang, L. Hu, G. N. Fuller, and W. Zhang, "An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin α5 is essential for IGFBP2-induced cell mobility," The Journal of Biological Chemistry, Vol. 281, no. 20, pp. 14085-14091, 2006.
163. J. S. M. de Mellow and R. C. Baxter, "Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts," Biochemical and Biophysical Research Communications, Vol. 156, no. 1, pp. 199-204, 1988.
164. W. F. Blum, E. W. Jenne, F. Reppin, K. Kietzmann, M. B. Ranke, and J. R. Bierich, "Insulin-like growth factor I (IGF-I)-binding protein complex is a better mitogen than free IGF-I," Endocrinology, Vol. 125, no. 2, pp. 766-772, 1989.
165. J. L. Martin, M. Z. Lin, E. M. McGowan, and R. C. Baxter, "Potentiation of growth factor signaling by insulin-like growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activity," The Journal of Biological Chemistry, Vol. 284, no. 38, pp. 25542-25552, 2009.
166. S. Y. Heazlewood, R. J. Neaves, B. Williams, D. N. Haylock, T. E. Adams, and S. K. Nilsson, "Megakaryocytes co-localise with hemopoietic stem cells and release cytokines that up-regulate stem cell proliferation," Stem Cell Research, Vol. 11, no. 2, pp. 782-792, 2013.
167. C. A. Conover, "Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism," Endocrinology, Vol. 130, no. 6, pp. 3191-3199, 1992.
168. W.-Y. Kim, M.-J. Kim, H. Moon et al., "Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development," Endocrinology, Vol. 152, no. 6, pp. 2164-2173, 2011.
169. B. Bartling, A. Koch, A. Simm, R. Scheubel, R. E. Silber, and A. N. Santos, "Insulin-like growth factor binding proteins-2 and -4 enhance the migration of human CD34-/CD133+ hematopoietic stem and progenitor cells," International Journal of Molecular Medicine, Vol. 25, no. 1, pp. 89-96, 2010.
170. R. A. Mosig, M. Lobl, E. Senturk et al., "IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer," Journal of Ovarian Research, Vol. 5, no. 1, article 3, 2012.
171. A. J. Butt, K. A. Dickson, F. McDougall, and R. C. Baxter, "Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo," The Journal of Biological Chemistry, Vol. 278, no. 32, pp. 29676-29685, 2003.
172. B. Tanno, V. Cesi, R. Vitali et al., "Silencing of endogenous IGFBP-5 by micro RNA interference affects proliferation, apoptosis and differentiation of neuroblastoma cells," Cell Death and Differentiation, Vol. 12, no. 3, pp. 213-223, 2005.
173. C. McCaig, C. M. Perks, and J. M. P. Holly, "Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin," Journal of Cell Science, Vol. 115, no. 22, pp. 4293-4303, 2002.
174. S. K. Johnson and R. S. Haun, "Insulin-like growth factor binding protein-5 influences pancreatic cancer cell growth," World Journal of Gastroenterology, Vol. 15, no. 27, pp. 3355-3366, 2009.
175. X. L. Xu, T. C. Lee, N. Offor et al., "Tumor-associated retinal astrocytes promote retinoblastoma cell proliferation through production of IGFBP-5," The American Journal of Pathology, Vol. 177, no. 1, pp. 424-435, 2010.
176. A. Sokolović, M. Sokolović, W. Boers, R. P. O. Elferink, and P. J. Bosma, "Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells," Fibrogenesis and Tissue Repair, Vol. 3, article 3, 2010.
177. L. J. Cobb, D. A. M. Salih, I. Gonzalez et al., "Partitioning of IGFBP-5 actions in myogenesis: IGF-independent antiapoptotic function," Journal of Cell Science, Vol. 117, part 9, pp. 1737-1746, 2004.
178. H. Miyake, M. Pollak, and M. E. Gleave, "Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models," Cancer Research, Vol. 60, no. 11, pp. 3058-3064, 2000.
179. P. Fu, J. A. Thompson, and L. A. Bach, "Promotion of cancer cell migration: An insulin-like growth factor (IGF)-independent action of IGF-binding protein-6," Journal of Biological Chemistry, Vol. 282, no. 31, pp. 22298-22306, 2007.
180. P. Fu, Z. Yang, and L. A. Bach, "Prohibitin-2 binding modulates insulin-like growth factor-binding protein-6 (IGFBP-6)-induced rhabdomyosarcoma cell migration," The Journal of Biological Chemistry, Vol. 288, no. 41, pp. 29890-29900, 2013.
181. P. Ye, Y. Xing, Z. Dai, and A. J. D'Ercole, "In vivo actions of insulin-like growth factor-I (IGF-I) on cerebellum development in transgenic mice: evidence that IGF-I increases proliferation of granule cell progenitors," Developmental Brain Research, Vol. 95, no. 1, pp. 44-54, 1996.
182. P. Ye and J. D'Ercole, "Insulin-like growth factor I (IGF-I) regulates IGF binding protein-5 gene expression in the brain," Endocrinology, Vol. 139, no. 1, pp. 65-71, 1998.
183. J. Wang, W. Niu, Y. Nikiforov et al., "Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice," The Journal of Clinical Investigation, Vol. 100, no. 6, pp. 1425-1439, 1997.
184. G. Zhao, R. L. Sutliff, C. S. Weber et al., "Smooth muscletargeted overexpression of insulin-like growth factor I results in enhanced vascular contractility," Endocrinology, Vol. 142, no. 2, pp. 623-632, 2001.
185. B. Zhu, G. Zhao, D. P. Witte, D. Y. Hui, and J. A. Fagin, "Targeted overexpression of IGF-I in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury," Endocrinology, Vol. 142, no. 8, pp. 3598-3606, 2001.
186. M. K. Dyck, A. F. Parlow, J.-F. Sénéchal, M.-A. Sirard, and F. Pothier, "Ovarian expression of human insulin-like growth factor-I in transgenic mice results in cyst formation," Molecular Reproduction and Development, Vol. 59, no. 2, pp. 178-185, 2001.
187. J. DiGiovanni, K. Kiguchi, A. Frijhoff et al., "Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice," Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, no. 7, pp. 3455-3460, 2000.
188. S. Clément, S. Refetoff, B. Robaye, J. E. Dumont, and S. Schurmans, "Low TSH requirement and goiter in transgenic mice overexpressing IGF-I and IGF-I receptor in the thyroid gland," Endocrinology, Vol. 142, no. 12, pp. 5131-5139, 2001.
189. L.-T. Busund, E. Richardsen, R. Busund et al., "Significant expression of IGFBP2 in breast cancer compared with benign lesions," Journal of Clinical Pathology, Vol. 58, no. 4, pp. 361-366, 2005.
190. M. L. Neuhouser, E. A. Platz, C. Till et al., "Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial," Cancer Prevention Research, Vol. 6, no. 2, pp. 91-99, 2013.
191. A. J. Butt, S. M. Firth, M. A. King, and R. C. Baxter, "Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells," The Journal of Biological Chemistry, Vol. 275, no. 50, pp. 39174-39181, 2000.
192. N. Miyakoshi, X. Qin, Y. Kasukawa et al., "Systemic administration of insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism," Endocrinology, Vol. 142, no. 6, pp. 2641-2648, 2001.
193. A. Parker, A. Gockerman, W. H. Busby, and D. R. Clemmons, "Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells," Endocrinology, Vol. 136, no. 6, pp. 2470-2476, 1995.
194. M. Iwashita, Y. Kudo, and Y. Takeda, "Effect of follicle stimulating hormone and insulin-like growth factors on proteolysis of insulin-like growth factor binding protein-4 in human granulosa cells," Molecular Human Reproduction, Vol. 4, no. 4, pp. 401-405, 1998.
195. S. Mazerbourg, M. T. Overgaard, C. Oxvig et al., "Pregnancy-associated plasma protein-A (PAPP-A) in ovine, bovine, porcine, and equine ovarian follicles: involvement in IGF binding protein-4 proteolytic degradation and mRNA expression during follicular development," Endocrinology, Vol. 142, no. 12, pp. 5243-5253, 2001.
196. S. Swami, N. Raghavachari, U. R. Muller, Y. P. Bao, and D. Feldman, "Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray," Breast Cancer Research and Treatment, Vol. 80, no. 1, pp. 49-62, 2003.
197. H. Huynh, X. F. Yang, and M. Pollak, "A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780," Cell Growth and Differentiation, Vol. 7, no. 11, pp. 1501-1506, 1996.
198. L. A. Bach, "IGFBP-6 five years on; not so "forgotten"?" Growth Hormone and IGF Research, Vol. 15, no. 3, pp. 185-192, 2005.
199. L. A. Bach, "Insulin-like growth factor binding protein-6: the "forgotten" binding protein?" Hormone and Metabolic Research, Vol. 31, no. 2-3, pp. 226-234, 1999.
200. P. Jean Ho and R. C. Baxter, "Characterization of truncated insulin-like growth factor-binding protein-2 in human milk," Endocrinology, Vol. 138, no. 9, pp. 3811-3818, 1997.
201. S. Réhault, P. Monget, S. Mazerbourg et al., "Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3," European Journal of Biochemistry, Vol. 268, no. 10, pp. 2960-2968, 2001.
202. S. Miyamoto, M. Nakamura, K. Yano et al., "Matrix metalloproteinase-7 triggers the matricrine action of insulinlike growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix," Cancer Science, Vol. 98, no. 5, pp. 685-691, 2007.
203. P. Monget, S. Mazerbourg, T. Delpuech et al., "Pregnancy-associated plasma protein-A is involved in insulin-like growth factor binding protein-2 (IGFBP-2) proteolytic degradation in bovine and porcine preovulatory follicles: identification of cleavage site and characterization of IGFBP-2 degradation," Biology of Reproduction, Vol. 68, no. 1, pp. 77-86, 2003.
204. U. Berg, P. Bang, and C. Carlsson-Skwirut, "Calpain proteolysis of insulin-like growth factor binding protein (IGFBP) -2 and -3, but not of IGFBP-1," Biological Chemistry, Vol. 388, no. 8, pp. 859-863, 2007.
205. B. A. Booth, M. Boes, and R. S. Bar, "IGFBP-3 proteolysis by plasmin, thrombin, serum: heparin binding, IGF binding, and structure of fragments," The American Journal of Physiology - Endocrinology and Metabolism, Vol. 271, no. 3, pp. E465-E470, 1996.
206. C. Lalou, S. Sawamura, B. Segovia, Y. Ogawa, and M. Binoux, "Proteolytic fragments of insulin-like growth factor binding protein-3: N-terminal sequences and relationships between structure and biological activity," Comptes Rendus de l'Academie des Sciences - Serie III, Vol. 320, no. 8, pp. 621-628, 1997.
207. E. Okabe, J.-I. Kajihara, Y. Usami, and K. Hirano, "The cleavage site specificity of human prostate specific antigen for insulinlike growth factor binding protein-3," FEBS Letters, Vol. 447, no. 1, pp. 87-90, 1999.
208. H. Salahifar, S. M. Firth, R. C. Baxter, and J. L. Martin, "Characterization of an amino-terminal fragment of insulinlike growth factor binding protein-3 and its effects in MCF-7 breast cancer cells," Growth Hormone and IGF Research, Vol. 10, no. 6, pp. 367-377, 2000.
209. S. D. Chernausek, C. E. Smith, K. L. Duffin, W. H. Busby, G. Wright, and D. R. Clemmons, "Proteolytic cleavage of insulinlike growth factor binding protein 4 (IGFBP-4). Localization of cleavage site to non-homologous region of native IGFBP-4," The Journal of Biological Chemistry, Vol. 270, no. 19, pp. 11377-11382, 1995.
210. C. Rees, D. R. Clemmons, G. D. Horvitz, J. B. Clarke, and W. H. Busby, "A protease-resistant form of insulin-like growth factor (IGF) binding protein 4 inhibits IGF-1 actions," Endocrinology, Vol. 139, no. 10, pp. 4182-4188, 1998.
211. C. A. Conover, S. K. Durham, J. Zapf, F. R. Masiarz, and M. C. Kiefer, "Cleavage analysis of insulin-like growth factor (IGF)-dependent IGF-binding protein-4 proteolysis and expression of protease-resistant IGF-binding protein-4 mutants," Journal of Biological Chemistry, Vol. 270, no. 9, pp. 4395-4400, 1995.
212. J. B. Lawrence, C. Oxvig, M. T. Overgaard et al., "The insulinlike growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A," Proceedings of the National Academy of Sciences of the United States of America, Vol. 96, no. 6, pp. 3149-3153, 1999.
213. Y. Imai, W. H. Busby Jr., C. E. Smith et al., "Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture," Journal of Clinical Investigation, Vol. 100, no. 10, pp. 2596-2605, 1997.
214. M. T. Overgaard, H. B. Boldt, L. S. Laursen, L. Sottrup-Jensen, C. A. Conover, and C. Oxvig, "Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase," The Journal of Biological Chemistry, Vol. 276, no. 24, pp. 21849-21853, 2001.
215. B. Zheng, J. B. Clarke, W. H. Busby, C. Duan, and D. R. Clemmons, "Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin," Endocrinology, Vol. 139, no. 4, pp. 1708-1714, 1998.
216. C. García-Echeverría, M. A. Pearson, A. Marti et al., "In vivo antitumor activity of NVP-AEW541 - A novel, potent, and selective inhibitor of the IGF-IR kinase," Cancer Cell, Vol. 5, no. 3, pp. 231-239, 2004.
217. S. Wolf, J. Lorenz, J. Mössner, and M. Wiedmann, "Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance," World Journal of Gastroenterology, Vol. 16, no. 2, pp. 156-166, 2010.
218. A. Girnita, L. Girnita, F. Del Prete, A. Bartolazzi, O. Larsson, and M. Axelson, "Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth," Cancer Research, Vol. 64, no. 1, pp. 236-242, 2004.
219. D. Vasilcanu, A. Girnita, L. Girnita, R. Vasilcanu, M. Axelson, and O. Larsson, "The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulinlike growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway," Oncogene, Vol. 23, no. 47, pp. 7854-7862, 2004.
220. R. Vasilcanu, D. Vasilcanu, L. Rosengren et al., "Picrop-odophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and β-arrestin1," Oncogene, Vol. 27, no. 11, pp. 1629-1638, 2008.
221. E. Menu, H. Jernberg-Wiklund, H. de Raeve et al., "Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival," International Journal of Cancer, Vol. 121, no. 8, pp. 1857-1861, 2007.
222. M. A. Economou, S. Andersson, D. Vasilcanu et al., "Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma," Investigative Ophthalmology and Visual Science, Vol. 49, no. 6, pp. 2337-2342, 2008.
223. J. Rodon, V. DeSantos, R. J. Ferry Jr., and R. Kurzrock, "Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials," Molecular Cancer Therapeutics, Vol. 7, no. 9, pp. 2575-2588, 2008.
224. J. A. Toretsky, S. M. Steinberg, M. Thakar et al., "Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors," Cancer, Vol. 92, no. 11, pp. 2941-2947, 2001.
225. A. P. Majumdar, S. Banerjee, J. Nautiyal et al., "Curcumin synergizes with resveratrol to inhibit colon cancer," Nutrition and Cancer, Vol. 61, no. 4, pp. 544-553, 2009.
226. Y. Li and T. Zhang, "Targeting cancer stem cells by curcumin and clinical applications," Cancer Letters, Vol. 346, no. 2, pp. 197-205, 2014.
227. M. A. Babcook and S. Gupta, "Apigenin: a promising anticancer agent for the modulation of the Insulin-like Growth Factor (IGF) axis in prostate cancer," Biomedical Research, Vol. 23, supplement 1, pp. 55-68, 2012.
228. M. Jung, S. Y. Bu, K.-H. Tak, J.-E. Park, and E. Kim, "Anticarcinogenic effect of quercetin by inhibition of insulin-like growth factor (IGF)-1 signaling in mouse skin cancer," Nutrition Research and Practice, Vol. 7, no. 6, pp. 439-445, 2013.
229. X. Li, Y. Feng, J. Liu, X. Feng, K. Zhou, and X. Tang, "Epigallocatechin-3-gallate inhibits IGF-I-stimulated lung cancer angiogenesis through downregulation of HIF-1alpha and VEGF expression," Journal of Nutrigenetics and Nutrigenomics, Vol. 6, no. 3, pp. 169-178, 2013.
230. D. Chen and Q. P. Dou, "Tea polyphenols and their roles in cancer prevention and chemotherapy," International Journal of Molecular Sciences, Vol. 9, no. 7, pp. 1196-1206, 2008.
231. S. Mondal, S. Bandyopadhyay, M. K. Ghosh, S. Mukhopadhyay, S. Roy, and C. Mandal, "Natural products: promising resources for cancer drug discovery," Anti-Cancer Agents in Medicinal Chemistry, Vol. 12, no. 1, pp. 49-75, 2012.
232. N. Sultana, "Clinically useful anticancer, antitumor, and antiwrinkle agent, ursolic acid and related derivatives as medicinally important natural product," Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 26, no. 5, pp. 616-642, 2011.
233. Y.-J. Surh, "Cancer chemoprevention with dietary phytochemicals," Nature Reviews Cancer, Vol. 3, no. 10, pp. 768-780, 2003.
234. N. Khan, N. Hadi, F. Afaq, D. N. Syed, M.-H. Kweon, and H. Mukhtar, "Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice," Carcinogenesis, Vol. 28, no. 1, pp. 163-173, 2007.
235. C. A. Lamartiniere, M. S. Cotroneo, W. A. Fritz, J. Wang, R. Mentor-Marcel, and A. Elgavish, "Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate," The Journal of Nutrition, Vol. 132, no. 3, pp. 552s-558s, 2002.
236. Y. Li and F. H. Sarkar, "Gene expression profiles of genistein-treated PC3 prostate cancer cells," The Journal of Nutrition, Vol. 132, no. 12, pp. 3623-3631, 2002.
237. S. R. Chinni, Y. Li, S. Upadhyay, P. K. Koppolu, and F. H. Sarkar, "Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells," Oncogene, Vol. 20, no. 23, pp. 2927-2936, 2001.
238. Y. Li, X. Li, and F. H. Sarkar, "Gene expression profiles of 13C-and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis," Journal of Nutrition, Vol. 133, no. 4, pp. 1011-1019, 2003.
239. K. Hastak, S. Gupta, N. Ahmad, M. K. Agarwal, M. L. Agarwal, and H. Mukhtar, "Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells," Oncogene, Vol. 22, no. 31, pp. 4851-4859, 2003.